BHWM
LOGC

Beaird Harris Wealth Management’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Beaird Harris Wealth Management’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-114
Closed – – 794
2022
Q3 		$0 Hold
114
– – ﹤0.01% 552
2022
Q2 		$0 Hold
114
– – ﹤0.01% 666
2022
Q1 		$0 Hold
114
– – ﹤0.01% 768
2021
Q4 		$0 Buy
+114
New +$386 ﹤0.01% 683

Beaird Harris Wealth Management's LOGC Position: Q4 2022 in Review

Beaird Harris Wealth Management sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 114 shares.

Beaird Harris Wealth Management first reported a position in LOGC in Q4 2021 and held it in 4 quarters. The position peaked at $0 in Q3 2022. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

  • Beaird Harris Wealth Management reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Beaird Harris Wealth Management sold 114 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022.
  • Beaird Harris Wealth Management first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • Beaird Harris Wealth Management's LogicBio Therapeutics, Inc. Common Stock position peaked at $0 in Q3 2022.
  • 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Beaird Harris Wealth Management's 13F filing for Q4 2022, filed 14 Feb 2023.